×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
ON DEMAND - Hype or Hope: Quantifying the Risk of Patients with Complex Diseases
Session Chair(s)
Matt Baldwin, MS
Biomedical Data Stewardship Senior Manager
Amgen, United States
Risk scores offer hopes and challenges in their quantification for patients with complex diseases. This session will give an overview with case studies from clinical and drug development perspectives.
Learning Objective : Discuss the value of risk scores, their clinical utility and application in clinical development; Explain how to apply risk scores and describe the outcomes; Identify some of the current challenges associated with their use and propose risk mitigation strategies.
Speaker(s)
Risk Scores and Clinical Utility
Sivakumar Gowrisankar, PhD
Parexel International, United States
Director, Genomic Medicine
Statistical Evaluation of Risk Scores
Gene A. Pennello, PhD, MS
FDA, United States
Senior Mathematical Statistician, OSEL, DIDSR, CDRH
Genetic Risk Scores in Cancer
Meijuan Li, PhD
Foundation Medicine, United States
Vice President, Head of Biometrics and Biomarkers
Have an account?